|
시장보고서
상품코드
2091772
암로디핀베실산염 시장 규모, 점유율 및 성장 분석 : 제형별, 적응증별, 판매 채널별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Amlodipine Besylate Market Size, Share, and Growth Analysis, By Dosage Formulation Type, By Application Indication, By Sales Channel, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 암로디핀베실산염 시장 규모는 2024년에 38억 달러로 평가되며, 2025년 40억 1,000만 달러에서 2033년까지 62억 1,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 5.6%로 성장할 것으로 전망되고 있습니다.
전 세계 암로디핀베실산염 시장에서는 고혈압 및 협심증 치료에 사용되는 이 지속형 칼슘 채널 차단제에 대한 수요가 견고한 추세를 보이고 있습니다. 이러한 인기는 입증된 효능과 안전성 프로파일, 그리고 환자의 복약 순응도를 높이는 1일 1회 투여의 편의성에서 비롯됩니다. 특허 만료 후 제네릭 제약사의 시장 진입으로 가격이 대폭 하락했으며, 인도나 브라질 등 신흥 시장에서 약품의 접근성이 향상되었습니다. 임상 지침에 따르면 암로디핀은 1차 선택 약물로 인정받고 있으며, 표준 치료 프로토콜 내에서 그 위상이 확고히 자리 잡고 있습니다. 고령화에 따라 심혈관 질환의 유병률이 증가하고 있는 점도, 합리적인 가격의 강압제에 대한 수요를 더욱 부추기고 있습니다. 각 제약사는 생산에 대한 투자와 병용 요법 개발을 통해 이에 대응하고 있습니다. 또한 AI를 활용한 분석을 통해 유통 최적화와 헬스케어 수요에 대한 대응 능력이 향상되어, 시장의 성장과 확대 기회를 촉진하고 있습니다.
전 세계 암로디핀베실산염 시장의 성장 요인
전 세계 암로디핀베실산염 시장의 주요 성장 동인 중 하나는 전 세계에서 고혈압 및 심혈관 질환 유병률이 증가하고 있다는 점입니다. 생활 습관의 변화와 고령화가 이러한 질환의 발병률 증가에 기여하고 있으므로 암로디핀베실산염과 같은 효과적인 강압제에 대한 수요가 증가하고 있습니다. 또한 환자와 의료 종사자들 사이에서 혈압 관리와 심장 건강 유지의 중요성에 대한 인식이 높아지고 있는 것이 시장 확대를 지원하고 있습니다. 또한 제네릭 의약품의 개발로 인해 접근성과 가격 경쟁력이 향상되어, 다양한 지역에서 암로디핀베실산염의 채택을 더욱 촉진하고 있으며, 결과적으로 시장 성장을 촉진하고 있습니다.
세계 암로디핀베실산염 시장의 제약 요인
세계 암로디핀베실산염 시장의 주요 시장 억제요인 중 하나는 제네릭 의약품과의 경쟁 심화입니다. 이로 인해 브랜드 제품의 가격과 시장 점유율에 큰 하락 압력이 가해지고 있습니다. 특허가 만료됨에 따라 저가의 제네릭 의약품이 시장에 유입되면서, 오리지널 제약사의 이익률이 하락하고 있습니다. 이러한 경쟁 심화는 암로디핀베실산염의 신규 제제 개발 및 개량을 위한 연구개발에 대한 투자를 저해할 가능성이 있습니다. 또한 엄격한 규제 요건이나 신약 승인 절차가 장기화되는 등의 요인 역시 혁신적인 제품의 시장 진입을 더욱 제한하고 있으며, 이는 시장 전체의 침체를 초래하는 한 요인이 되고 있습니다.
세계 암로디핀베실산염 시장의 동향
전 세계 암로디핀베실산염 시장에서는 고정 용량 복합제에 대한 뚜렷한 추세가 나타나고 있습니다. 이는 암로디핀베실산염과 다른 강압제를 병용하는 ‘1정 요법’에 대한 의료진의 선호도가 높아지고 있음을 반영합니다. 이러한 변화는 치료 요법을 간소화하고, 환자의 복약 순응도를 높이며, 만성 심혈관 질환을 앓고 있는 사람들의 복약 부담을 줄일 필요성에 의해 추진되고 있습니다. 환자 중심의 치료를 위한 광범위한 움직임의 일환으로, 제약사들은 혁신적인 제형 연구에 주력하고 있으며, 포괄적인 제품을 출시하기 위한 규제 절차를 진행하고 있습니다. 이러한 동향은 다인자성 고혈압에 대처하는 동시에, 끊임없이 변화하는 의료 환경에서 비용 대비 효과가 높은 치료 전략을 추진하는 것을 목적으로 하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 암로디핀베실산염 시장 규모 : 제형 유형별
세계의 암로디핀베실산염 시장 규모 : 적응증별
세계의 암로디핀베실산염 시장 규모 : 판매 채널별
세계의 암로디핀베실산염 시장 규모 : 유통 채널별
세계의 암로디핀베실산염 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Amlodipine Besylate Market size was valued at USD 3.8 Billion in 2024 and is poised to grow from USD 4.01 Billion in 2025 to USD 6.21 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).
The global amlodipine besylate market showcases a strong demand for this long-acting calcium-channel blocker used to treat hypertension and angina. Its popularity stems from its proven effectiveness, safety profile, and convenient once-daily dosing, enhancing patient adherence. The entry of generic manufacturers after patent expiration has significantly reduced prices, increasing accessibility in emerging markets like India and Brazil. As per clinical guidelines, amlodipine is recognized as a first-line therapy, solidifying its status in standard care protocols. The rising prevalence of cardiovascular diseases among aging populations further fuels demand for affordable antihypertensive options. Manufacturers are responding by investing in production and developing combination therapies. Additionally, AI-driven analytics are optimizing distribution and enhancing responsiveness to healthcare needs, promoting market growth and expansion opportunities.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Amlodipine Besylate market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Amlodipine Besylate Market Segments Analysis
Global amlodipine besylate market is segmented by dosage formulation type, application indication, sales channel, distribution channel and region. Based on dosage formulation type, the market is segmented into Oral Tablets and Liquid Oral Suspensions. Based on application indication, the market is segmented into Hypertension Management and Coronary Artery Disease Treatment. Based on sales channel, the market is segmented into Online and Offline. Based on distribution channel, the market is segmented into Direct and Indirect. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Amlodipine Besylate Market
One of the key market drivers for the global Amlodipine Besylate market is the rising prevalence of hypertension and cardiovascular diseases worldwide. As lifestyle changes and an aging population contribute to increased incidences of these health conditions, the demand for effective antihypertensive medications like Amlodipine Besylate is on the rise. Furthermore, growing awareness about the importance of managing blood pressure and cardiac health among patients and healthcare professionals fuels the market's expansion. Additionally, the development of generic formulations enhances accessibility and affordability, further propelling the adoption of Amlodipine Besylate in various regions, thereby driving market growth.
Restraints in the Global Amlodipine Besylate Market
One significant market restraint for the global Amlodipine Besylate market is the rising prevalence of generic drug competition, which puts substantial downward pressure on prices and market share for brand-name products. As patent expirations occur, an influx of low-cost generic alternatives becomes available, leading to reduced profit margins for original manufacturers. This heightened competition can deter investment in research and development for new formulations or enhancements of Amlodipine Besylate. Additionally, stringent regulatory requirements and the lengthy approval process for new drugs can further limit the entry of innovative products, contributing to overall market stagnation.
Market Trends of the Global Amlodipine Besylate Market
The Global Amlodipine Besylate market is experiencing a significant trend towards fixed-dose combinations, reflecting a growing preference among healthcare providers for single-pill therapies that merge amlodipine besylate with additional antihypertensive medications. This shift is driven by the need to simplify treatment regimens, enhance patient adherence, and alleviate pill burden for individuals dealing with chronic cardiovascular issues. As part of a broader movement towards patient-centric care, pharmaceutical manufacturers are focusing on innovative formulation research and navigating regulatory pathways to introduce comprehensive products. This trend aims to address multifactorial hypertension while promoting cost-effective treatment strategies in an evolving healthcare landscape.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Amlodipine Besylate Market Size by Dosage Formulation Type & CAGR (2026-2033)
- Market Overview
- Oral Tablets
- 2.5 mg Tablets
- 5 mg Tablets
- 10 mg Tablets
- Liquid Oral Suspensions
Global Amlodipine Besylate Market Size by Application Indication & CAGR (2026-2033)
- Market Overview
- Hypertension Management
- Coronary Artery Disease Treatment
Global Amlodipine Besylate Market Size by Sales Channel & CAGR (2026-2033)
- Market Overview
- Online
- Offline
Global Amlodipine Besylate Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Direct
- Indirect
Global Amlodipine Besylate Market Size & CAGR (2026-2033)
- North America (Dosage Formulation Type, Application Indication, Sales Channel, Distribution Channel)
- US
- Canada
- Europe (Dosage Formulation Type, Application Indication, Sales Channel, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Dosage Formulation Type, Application Indication, Sales Channel, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Dosage Formulation Type, Application Indication, Sales Channel, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Dosage Formulation Type, Application Indication, Sales Channel, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Viatris
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Aurobindo Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Torrent Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Zydus Lifesciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Hikma Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
